New Purdue ER/LA ABT approved by FDA!

Quote













Anonymous said:
You both are idiots. What was approved is not competing with an immediate release opiod.
Click to expand...

All three of you are idiots. No one said anything about an immediate release opioid and it was targiniq ER that was approved today, which will be competing in the same ER/LA market as Zohydro ER, but it is an Oxycodone product Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), not hydrocodone. Purdue already has the oxy market cornered so this product will most likely replace its own products in the market place.
 



Anonymous said:
All three of you are idiots. No one said anything about an immediate release opioid and it was targiniq ER that was approved today, which will be competing in the same ER/LA market as Zohydro ER, but it is an Oxycodone product Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), not hydrocodone. Purdue already has the oxy market cornered so this product will most likely replace its own products in the market place.
Click to expand...

You are just as wrong as the others. Targiniq AND Butrans were both approved today. One is transdermal buprenorphine and the other is ER oxycodone with naloxone. Don't go insulting someone else if you can't provide complete information.
 






I don't know why there is so much confusion. Purdue's Butrans has been around for a few years. Nothing new there. the new addition to their portfolio is Targiniq, a long acting oxycodone with the same ADT Embeda had, and it is included in their label, just like Oxycontin's is. While it is not a long acting HYDROCODONE, don't kid yourself, any new product in the pain space especially another ER/LA product IS a competitor. It remains to be seen how much of a threat Targiniq will be to Zohydro ER, but expect plenty of noise. It's Purdue after all.
 



Anonymous said:
I don't know why there is so much confusion. Purdue's Butrans has been around for a few years. Nothing new there. the new addition to their portfolio is Targiniq, a long acting oxycodone with the same ADT Embeda had, and it is included in their label, just like Oxycontin's is. While it is not a long acting HYDROCODONE, don't kid yourself, any new product in the pain space especially another ER/LA product IS a competitor. It remains to be seen how much of a threat Targiniq will be to Zohydro ER, but expect plenty of noise. It's Purdue after all.
Click to expand...
 






Top Bottom
Back
Quote